ReviewArchives of microbiology2026
Silybum marianum against multidrug-resistant bacterial pathogens: mechanisms of action, synergistic therapy, nanoformulations, and clinical translation.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silybum marianum, commonly known as milk thistle, has a long history of medicinal use as a hepatoprotective plant and has emerged as a potential source of natural antimicrobial agents against multidrug-resistant (MDR) bacterial pathogens. This review provides an objective overview of current knowledge on the antimicrobial mechanisms of S. marianum and its potential utility for targeting resistant bacterial strains. Recent studies have demonstrated that silymarin, the major flavonolignan complex isolated from the seeds of S. marianum, exhibits observable antimicrobial activity against several critical MDR phenotypes, including methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, carbapenem-resistant Klebsiella pneumoniae, and Stenotrophomonas maltophilia. The antimicrobial effect of silymarin is concentration-dependent, with ethanolic extracts exhibiting greater antibacterial activity than aqueous extracts. The principal mechanisms underlying the anti-MDR activity of S. marianum include multiple pathways: disruption of bacterial membranes, increasing permeability; inhibition of biofilm formation; modulation of reactive oxygen species; inhibition of efflux pumps; and synergistic enhancement of conventional antibiotic activity. Advanced nanoformulation techniques have been applied to address the poor baseline bioavailability of silymarin, with nano-silymarin systems displaying lower minimum inhibitory concentrations (MICs) than conventional formulations against clinical MDR isolates in laboratory models. Topical delivery systems, such as mucoadhesive gels, offer sustained drug release profiles and enhanced permeation properties. Nevertheless, standardising extraction protocols, optimising dosing regimens, and conducting rigorous clinical trials remain essential steps to translate these preclinical findings into viable human therapeutic applications.
Indexed as
Identifiers
42766136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.